Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2773 - Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized Phase II study

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Ulrich-Frank Pape

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

U. Pape1, S. Kasper2, J. Meiler3, M. Sinn4, A. Vogel5, L. Mueller6, O. Burkhard7, K. Caca8, S. Heeg9, V. Rodriguez Laval10, A.A. Kuhl11, R. Arsenic12, H. Jansen13, T. Mehrling14, K. Hilgier14, I. Wagner14, N. Utku10

Author affiliations

  • 1 Innere Medizin Und Gastroenterologie, Asklepios Klinik St. Georg, 20099 - Hamburg/DE
  • 2 Medical Oncology, University Hospital Essen Westdeutsches Tumorzentrum, 45147 - Essen/DE
  • 3 Department Of Medical Oncology, West German Cancer Center, University Hospital Essen, 45147 - Essen/DE
  • 4 Department Of Medical Oncology, Universitätsklinik Charité, Campus Virchow Klinikum, 13353 - Berlin/DE
  • 5 Klinik Für Gastroenterologie, Hepatologie & Endokrinologie, Hannover Medical School, 30625 - Hannover/DE
  • 6 Onkologie Unterems Leer Emden Papenburg, Onkologische Schwerpunktpraxis Leer-Emden, 26789 - Leer/DE
  • 7 Own Practice, Dr. Oswald Burkhard, 67547 - Worms/DE
  • 8 Klinik Für Innere Medizin, Gastroenterologie, Hämato-onkologie, Pneumologie, Diabetologie Und Infektiologie In Ludwigsburg, Klinikum Ludwigsburg Medizinische Klinik I, 71640 - Ludwigsburg/DE
  • 9 Zentrum Gastrointestinale Tumore, Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, 79106 - Freiburg im Breisgau/DE
  • 10 Biomedizinzentrumdortmund, CellAct Pharma GmbH, D-44227 - Dortmund/DE
  • 11 Core Unit Of The Charite, iPATH Berlin, 12203 - Berlin/DE
  • 12 Institute Of Pathology, Charité Universitätsmedizin Berlin, 10117 - Berlin/DE
  • 13 Institute For Medical Immunology, Charité Universitätsmedizin, 13353 - Berlin/DE
  • 14 Vi, Mundipharma EDO GmbH, 4020 - Basel/CH

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2773

Background

Etoposide toniribate (also known as EDO-S7.1, and previously known as CAP7.1), a novel topoisomerase II inhibitor, is activated in the presence of carboxylesterases. In specific tumor cell lines, it was found to be more active than etoposide, with in vivo activity demonstrated in several drug-resistant tumor models. Anti-tumor activity was confirmed in a Phase II randomized study in patients (pts) with relapsed BTC.

Methods

Pts with BTC and disease progression after ≥1 line of chemotherapy were randomized 1:1 to 3-week cycles of etoposide toniribate (200 or 150mg/m2; iv on days 1–5), or best supportive care (BSC). Pts who progressed on BSC crossed over to receive etoposide toniribate. Efficacy data collected after crossover were evaluated separately as part of this post-hoc exploratory analysis.

Results

The per protocol analysis set included 19 pts: 10 pts were randomized to BSC, and crossed over to etoposide toniribate after disease progression, 9 pts were randomized directly to the etoposide toniribate treatment arm. Treatment after crossover from BSC to etoposide toniribate was associated with a trend for improved disease control: n/N (%; 95% CI) 4/10 (40%; 12.2, 73.8) vs 2/10 (20%; 2.5, 55.6), with tumor control achieved in 4/10 patients (1 pt partial response, 3 pts stable disease). Risk of disease progression was 2.33 times higher during BSC treatment vs after crossover to etoposide toniribate. Crossover from BSC to etoposide toniribate was associated with a trend for prolonged median PFS (39 vs 50 days). Median OS for pooled etoposide toniribate and crossover pts was 145 (59, 243) days, estimated 1-year OS 14.1%. Median (95% CI) OS for etoposide toniribate vs crossover pts was 180 (43, 468) vs 83 (11, 243) days, HR 0.39 (0.13, 1.18), estimated 1-year OS 29.6% (5.2%, 60.7%) vs 0%.

Conclusions

This post-hoc analysis provides further evidence for the efficacy of etoposide toniribate and suggests that early initiation in pts with advanced BTC may offer a potential survival benefit. The efficacy of etoposide toniribate will be further investigated in a planned phase III study. Funding: CellAct Pharm GmbH and Mundipharma EDO GmbH.

Clinical trial identification

NCT02094560.

Editorial acknowledgement

Sarah Birch, PhD, at Makara Health Communications Ltd, UK, funded by Mundibiopharma Ltd.

Legal entity responsible for the study

CellAct Pharma GmbH.

Funding

CellAct Pharma GmbH, Mundipharma EDO GmbH.

Disclosure

U. Pape: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Shire; Honoraria (self), Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Ipsen. S. Kasper: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy: Servier; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Merck; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: MSD; Research grant / Funding (self): Celgene; Research grant / Funding (self), Travel / Accommodation / Expenses: Lilly. J. Meiler: Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Sanofi/Aventis. M. Sinn: Honoraria (self): Amgen; Honoraria (self), Research grant / Funding (self): Leo Pharma; Honoraria (self), Advisory / Consultancy: Sanofi; Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Boston Biomedical; Research grant / Funding (self): Incyte; Research grant / Funding (self): Merck Sharp and Dohme; Research grant / Funding (self): Servier; Research grant / Funding (self): Taiho Pharmaceutical. H. Jansen: Advisory / Consultancy: CellAct Pharma. T. Mehrling: Leadership role, Full / Part-time employment: Mundipharma EDO. K. Hilgier: Advisory / Consultancy: Mundipharma EDO. I. Wagner: Full / Part-time employment: Mundipharma EDO. N. Utku: Honoraria (self), Advisory / Consultancy, Leadership role, Research grant / Funding (self), Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: CellAct Pharma; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Mundipharma EDO; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.